Bispecific T cell engagers (BiTE®) are a robust class of immuno-oncology (I/O) therapy which are engineered proteins that redirect T cells to destroy targeted tumor cells. BiTEs are being studied in patients with high and low tumor burden, rapidly progressing disease and across different treatment lines. Despite progress in this field, a significant proportion of patients are still refractory or suffer relapse and therefore strategies are needed to extend durable responses to a wider patient population.
In this webinar, Dr. Ludovic Bourre discusses the translational challenges in BiTE development and explores how next-generation preclinical models can be used to provide critical insights in early-stage BiTE development.
Dr. Ludovic Bourre, Director of Scientific Engagement at Crown Bioscience brings over 13 years of research experience in the fields of oncology and immuno-oncology, from both academia and commercial organizations. Previously, Ludovic worked at Invectys as head of the pharmacology department, with his experience covering cancer vaccines and antibody immunotherapy from preclinical to early clinical phases.